These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 25486450)

  • 1. Human immunodeficiency virus post-exposure prophylaxis: primum non nocere.
    Alves M; Janneau-Magrino L; Legendre N; Pateron D; Guidet B; Yordanov Y
    Am J Med; 2015 Apr; 128(4):e3-4. PubMed ID: 25486450
    [No Abstract]   [Full Text] [Related]  

  • 2. Ergotism with acute limb ischemia, provoked by HIV protease inhibitors interaction with ergotamine, rescued by multisite transluminal balloon angioplasty.
    Mohamedi N; Mirault T; Durivage A; Di Primio M; Khider L; Detriche G; El Batti S; Sapoval M; Messas E; Goudot G
    J Med Vasc; 2021 Feb; 46(1):13-21. PubMed ID: 33546816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine.
    Diaz-Brito V; León A; Knobel H; Peraire J; Domingo P; Clotet B; Dalmau D; Cruceta A; Arnaiz JA; Gatell JM; García F;
    Antivir Ther; 2012; 17(2):337-46. PubMed ID: 22293542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Side effects and tolerability of post-exposure prophylaxis with zidovudine, lamivudine, and lopinavir/ritonavir: a comparative study with HIV/AIDS patients.
    Cai J; Xiao J; Zhang Q
    Chin Med J (Engl); 2014; 127(14):2632-6. PubMed ID: 25043080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COMPARATIVE EFFICIENCY OF APPLICATION OF DIFFERENT THERAPEUTIC SCHEMES FOR POST-CONTACT PREVENTION OF HIV INFECTION IN HEALTH PROVIDERS.
    Vorob'eva NN; Ivanova ES; Krasnoperova NN; Okishev MA
    Klin Med (Mosk); 2016; 94(4):295-299. PubMed ID: 28957610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Burning Pain in the Legs.
    Reghukumar A; Benson R
    N Engl J Med; 2020 Jul; 383(4):e18. PubMed ID: 32706537
    [No Abstract]   [Full Text] [Related]  

  • 7. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
    Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
    J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerability of HIV postexposure prophylaxis with tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation.
    Tosini W; Muller P; Prazuck T; Benabdelmoumen G; Peyrouse E; Christian B; Quertainmont Y; Bouvet E; Rabaud C
    AIDS; 2010 Sep; 24(15):2375-80. PubMed ID: 20729709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Headache in an HIV-Positive Patient: Dangerous Interaction.
    Iardino A; Garner O; Lorusso G; Lotta F
    BMJ Case Rep; 2018 Jun; 2018():. PubMed ID: 29866692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection.
    Rabaud C; Burty C; Grandidier M; Christian B; Penalba C; Béguinot I; Jeanmaire H; May T
    Clin Infect Dis; 2005 Jan; 40(2):303-5. PubMed ID: 15655751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
    Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
    AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA.
    Feeney ER; van Vonderen MG; Wit F; Danner SA; van Agtmael MA; Villarroya F; Domingo P; Capeau J; Reiss P; Mallon PW;
    AIDS; 2012 Nov; 26(17):2165-74. PubMed ID: 22874517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicians experiment with post-exposure drug pairs.
    AIDS Alert; 1996 Feb; 11(2):16-7. PubMed ID: 11363233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers.
    Park SY; Lee JS; Son JS; Ko JH; Peck KR; Jung Y; Woo HJ; Joo YS; Eom JS; Shi H
    J Hosp Infect; 2019 Jan; 101(1):42-46. PubMed ID: 30240813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebral ergotism under treatment with ergotamine and ritonavir.
    Spiegel M; Schmidauer C; Kampfl A; Sarcletti M; Poewe W
    Neurology; 2001 Aug; 57(4):743-4. PubMed ID: 11524501
    [No Abstract]   [Full Text] [Related]  

  • 17. HIV exposure through contact with body fluids.
    Prescrire Int; 2012 Apr; 21(126):100-1, 103-5. PubMed ID: 22515138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Splenic infarction. Ergotism induced by ritonavir?].
    Dal Verme A; López E; Grinspon S; Fernández Pardal R; Mengia M; Mazzocchi O
    Medicina (B Aires); 2012; 72(6):475-7. PubMed ID: 23241290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.
    van Vonderen MG; Lips P; van Agtmael MA; Hassink EA; Brinkman K; Geerlings SE; Sutinen J; Ristola M; Danner SA; Reiss P
    AIDS; 2009 Jul; 23(11):1367-76. PubMed ID: 19424051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is known about the action of dihydroergotamine on the vasculature in man?
    Müller-Schweinitzer E
    Int J Clin Pharmacol Ther Toxicol; 1984 Dec; 22(12):677-82. PubMed ID: 6396240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.